Immunoassay for Biomarker Predicts Risk of Heart Failure
|
By LabMedica International staff writers Posted on 26 Jan 2011 |
|
An enzyme-linked immunosorbent assay (ELISA) that measures galectin-3 in human plasma has been used to calculate the risk of heart failure (HF).
This ELISA assay quantitatively measures the concentration of human galectin-3 levels in EDTA plasma. This assay has high sensitivity with a lower limit of detection of 1.13 ng/mL) and exhibits no cross-reactivity with collagens or other members of the galectin family.
In a study carried out at the University Medical Center Groningen, (UMCG; Groningen, The Netherlands), blood samples were available from 592 heart failure patients during their index admission. Samples were also collected just before discharge when patients were stabilized and there was a mean follow-up of 18 months. Galectin-3 was measured by the ELISA method developed by BG Medicine (Waltham, MA, USA). Levels of cytokines vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), C-reactive protein (CRP), and transforming growth factor-β 1 (TGF-β 1) were measured in the same plasma samples using Search-Light Proteome Arrays (Aushon BioSystems, Billerica, MA, USA).
The investigators reported that the inflammatory markers were positively correlated to galectin-3 levels and the study confirmed that galectin-3 is a strong and independent predictor of adverse outcomes. The prognostic value of the galectin-3 biomarker remained even after adjustment for established risk factors for poor outcomes in HF, including age, sex, brain natriuretic peptide, renal function, and diabetes mellitus. The predictive power of plasma galectin-3 appears to be predominantly strong in heart failure patients with preserved left ventricular ejection fraction, which nowadays comprise about half of all HF patients. Serial measurements of galectin-3 do not appear to add to the prognostic power of single measurements. The details of the study were published in January 2011, in the journal Annals of Medicine.
Related Links:
University Medical Center Groningen
BG Medicine
Aushon BioSystems
.jpg)
This ELISA assay quantitatively measures the concentration of human galectin-3 levels in EDTA plasma. This assay has high sensitivity with a lower limit of detection of 1.13 ng/mL) and exhibits no cross-reactivity with collagens or other members of the galectin family.
In a study carried out at the University Medical Center Groningen, (UMCG; Groningen, The Netherlands), blood samples were available from 592 heart failure patients during their index admission. Samples were also collected just before discharge when patients were stabilized and there was a mean follow-up of 18 months. Galectin-3 was measured by the ELISA method developed by BG Medicine (Waltham, MA, USA). Levels of cytokines vascular endothelial growth factor (VEGF), interleukin-6 (IL-6), C-reactive protein (CRP), and transforming growth factor-β 1 (TGF-β 1) were measured in the same plasma samples using Search-Light Proteome Arrays (Aushon BioSystems, Billerica, MA, USA).
The investigators reported that the inflammatory markers were positively correlated to galectin-3 levels and the study confirmed that galectin-3 is a strong and independent predictor of adverse outcomes. The prognostic value of the galectin-3 biomarker remained even after adjustment for established risk factors for poor outcomes in HF, including age, sex, brain natriuretic peptide, renal function, and diabetes mellitus. The predictive power of plasma galectin-3 appears to be predominantly strong in heart failure patients with preserved left ventricular ejection fraction, which nowadays comprise about half of all HF patients. Serial measurements of galectin-3 do not appear to add to the prognostic power of single measurements. The details of the study were published in January 2011, in the journal Annals of Medicine.
Related Links:
University Medical Center Groningen
BG Medicine
Aushon BioSystems
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism
Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more
New Biomarkers to Improve Early Detection and Monitoring of Kidney Injury
Drug-induced kidney injury, also known as nephrotoxicity, is a prevalent issue in clinical practice, occurring when specific medications at certain doses cause damage to the kidneys. Nephrotoxicity can... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read more
Pathology
view channel
AI Model Predicts Patient Response to Bladder Cancer Treatment
Each year in the United States, around 81,000 new cases of bladder cancer are diagnosed, leading to approximately 17,000 deaths annually. Muscle-invasive bladder cancer (MIBC) is a severe form of bladder... Read more
New Laser-Based Method to Accelerate Cancer Diagnosis
Researchers have developed a method to improve cancer diagnostics and other diseases. Collagen, a key structural protein, plays various roles in cell activity. A novel multidisciplinary study published... Read more
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read more
Industry
view channel
Tecan Acquires ELISA Immunoassay Assets from Revvity's Cisbio Bioassays
Tecan Group (Männedorf, Switzerland) has entered into an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS (Codolet, France), a subsidiary of the... Read more
